Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hak Choy

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
Clinical Lung Cancer|May 10, 2011
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213Elizabeth Gore, Kyounghwa Bae, Corey Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocolChandra P Belani, Hak Choy, Phil Bonomi, et al.
Indian Journal of Biochemistry & Biophysics|September 8, 2006
Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinibJae-Chul Kim, M Aktar Ali, Animesh Nandi, et al.
Frontiers in Oncology|July 1, 2022
National Effort to Re-Establish Heavy Ion Cancer Therapy in the United StatesArnold Pompos, Robert L Foote, Albert C Koong, et al.
International Journal of Radiation Oncology, Biology, Physics|February 5, 2018
Real-Time Whole-Brain Radiation Therapy: A Single-Institution ExperienceAnh H Le, Strahinja Stojadinovic, Robert Timmerman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancerHak Choy, Anshu K Jain, Jennifer Moughan, et al.
International Journal of Radiation Oncology, Biology, Physics|August 21, 2007
DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitorElisabeth Kodym, Reinhard Kodym, Benjamin P Chen, et al.
JAMA Oncology|June 1, 2018
Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung CancerRobert D Timmerman, Chen Hu, Jeff M Michalski, et al.
Physics in Medicine and Biology|May 9, 2017
Multi-objective radiomics model for predicting distant failure in lung SBRTZhiguo Zhou, Michael Folkert, Puneeth Iyengar, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 2012
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lungMohan Suntharalingam, Rebecca Paulus, Martin J Edelman, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
Clinical Lung Cancer|May 10, 2011
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213Elizabeth Gore, Kyounghwa Bae, Corey Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocolChandra P Belani, Hak Choy, Phil Bonomi, et al.
Indian Journal of Biochemistry & Biophysics|September 8, 2006
Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinibJae-Chul Kim, M Aktar Ali, Animesh Nandi, et al.
Frontiers in Oncology|July 1, 2022
National Effort to Re-Establish Heavy Ion Cancer Therapy in the United StatesArnold Pompos, Robert L Foote, Albert C Koong, et al.
International Journal of Radiation Oncology, Biology, Physics|February 5, 2018
Real-Time Whole-Brain Radiation Therapy: A Single-Institution ExperienceAnh H Le, Strahinja Stojadinovic, Robert Timmerman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancerHak Choy, Anshu K Jain, Jennifer Moughan, et al.
International Journal of Radiation Oncology, Biology, Physics|August 21, 2007
DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitorElisabeth Kodym, Reinhard Kodym, Benjamin P Chen, et al.
JAMA Oncology|June 1, 2018
Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung CancerRobert D Timmerman, Chen Hu, Jeff M Michalski, et al.
Physics in Medicine and Biology|May 9, 2017
Multi-objective radiomics model for predicting distant failure in lung SBRTZhiguo Zhou, Michael Folkert, Puneeth Iyengar, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 2012
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lungMohan Suntharalingam, Rebecca Paulus, Martin J Edelman, et al.
Pageof 14